1. Search Result
Search Result
Results for "

Cachexia

" in MedChemExpress (MCE) Product Catalog:

28

Inhibitors & Agonists

5

Peptides

1

Inhibitory Antibodies

3

Natural
Products

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-156354

    Others Metabolic Disease
    GPR61 Inverse agonist 1 (Compound 1) is a GPR61 inverse agonist (IC50: 11 nM). GPR61 Inverse agonist 1 can be used for research of disorders of metabolism and body weight, such as obesity and cachexia .
    GPR61 Inverse agonist 1
  • HY-13676
    Megestrol acetate
    2 Publications Verification

    Progesterone Receptor Autophagy HIV Endocrinology Cancer
    Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia. Megestrol acetate decreases nuclear and cytosol androgen receptors human BPH tissue. Megestrol acetate has the potential for HIV study and downregulates autophagic catabolic pathway .
    Megestrol acetate
  • HY-148349

    Melanocortin Receptor Neurological Disease Metabolic Disease
    PF-07258669 is a melanocortin-4 receptor (MC4) antagonist. PF-07258669 can be used for the research of cachexia, anorexia, or anorexia nervosa .
    PF-07258669
  • HY-12176
    Aliskiren
    5+ Cited Publications

    CGP 60536; CGP60536B; SPP 100

    Renin Autophagy Cardiovascular Disease Cancer
    Aliskiren is an orally active, highly potent and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren can be used for the research of hypertension, cardiovascular diseases and cancer cachexia .
    Aliskiren
  • HY-P5971

    Melanocortin Receptor Metabolic Disease
    TCMCB07, a cyclic nonapeptide peptide, is an orally active and brain-penetrant melanocortin receptor 4 (MC4R) antagonist. TCMCB07 plays an important role in cachexia .
    TCMCB07
  • HY-12177
    Aliskiren hemifumarate
    5+ Cited Publications

    CGP 60536 hemifumarate; CGP60536B hemifumarate; SPP 100 hemifumarate

    Renin Autophagy Cardiovascular Disease Cancer
    Aliskiren (CGP 60536; CGP60536B; SPP 100) hemifumarate is an orally active and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren hemifumarate can be used for the research of hypertension, cardiovascular diseases and cancer cachexia .
    Aliskiren hemifumarate
  • HY-12176B

    CGP 60536 fumarate; CGP60536B fumarate; SPP 100 fumarate

    Renin Autophagy Cardiovascular Disease Cancer
    Aliskiren fumarate is an orally active, highly potent and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren fumarate can be used for the research of hypertension, cardiovascular diseases and cancer cachexia .
    Aliskiren fumarate
  • HY-P5971A

    Melanocortin Receptor Metabolic Disease
    TCMCB07 TFA, a cyclic nonapeptide peptide, is an orally active and brain-penetrant melanocortin receptor 4 (MC4R) antagonist. TCMCB07 TFA plays an important role in cachexia .
    TCMCB07 TFA
  • HY-12176A

    CGP 60536 hydrochloride; CGP60536B hydrochloride; SPP 100 hydrochloride

    Renin Autophagy Cardiovascular Disease Cancer
    Aliskiren (CGP 60536; CGP60536B; SPP 100) hydrochloride is an orally active and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren hydrochloride can be used for the research of hypertension, cardiovascular diseases and cancer cachexia - .
    Aliskiren hydrochloride
  • HY-12176R

    Renin Autophagy Cardiovascular Disease Cancer
    Aliskiren (Standard) is the analytical standard of Aliskiren. This product is intended for research and analytical applications. Aliskiren is an orally active, highly potent and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren can be used for the research of hypertension, cardiovascular diseases and cancer cachexia .
    Aliskiren (Standard)
  • HY-161875

    Histone Acetyltransferase Metabolic Disease Cancer
    NAT1-IN-1 (compound 350) is a potent N-acetyltransferase 1 (NAT1)-targeted inhibitor, with an IC50 of 44 nM. NAT1-IN-1 can be used for the research of hypermetabolic diseases such as amyotrophic lateral sclerosis, cancer cachexia, and sepsis .
    NAT1-IN-1
  • HY-100186
    GSK-2881078
    4 Publications Verification

    Androgen Receptor Cardiovascular Disease Others Metabolic Disease Inflammation/Immunology Endocrinology Cancer
    GSK-2881078 is an orally active and nonsteroidal selective androgen receptor modulator (SARM) which act as partial AR agonists in androgenic tissues while mainly as complete AR agonists in synthetic metabolic tissues,induces AR-mediated transcriptional activation in PC3(AR)2 cells (EC50 = 3.99 nM) and the effect can be inhibited by the non-steroidal AR antagonist Bicalutamide. GSK-2881078 can be used in research of muscle weakness and cachexia associated with both chronic and acute illness .
    GSK-2881078
  • HY-19884

    RM-131; BIM-28131

    GHSR Metabolic Disease
    Relamorelin (RM-131), a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin is centrally penetrant. Relamorelin increases growth hormone levels and accelerates gastric emptying. Relamorelin has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research .
    Relamorelin
  • HY-19884A

    RM-131 acetate; BIM-28131 acetate

    GHSR Metabolic Disease
    Relamorelin (RM-131) acetate, a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin acetate is centrally penetrant. Relamorelin acetate increases growth hormone levels and accelerates gastric emptying. Relamorelin acetate has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research .
    Relamorelin acetate
  • HY-19884B

    RM-131 TFA; BIM-28131 TFA

    GHSR Metabolic Disease
    Relamorelin (RM-131) TFA, a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin TFA is centrally penetrant. Relamorelin TFA increases growth hormone levels and accelerates gastric emptying. Relamorelin TFA has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research .
    Relamorelin TFA
  • HY-N0109
    Salidroside
    Maximum Cited Publications
    24 Publications Verification

    Rhodioloside

    PINK1/Parkin mTOR Apoptosis Prolyl Endopeptidase (PREP) Cancer
    Salidroside (Rhodioloside) is a prolyl endopeptidase inhibitor. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling. Salidroside protects dopaminergic neurons by enhancing PINK1/Parkin-mediated mitophagy.
    Salidroside
  • HY-N0109R

    Rhodioloside (Standard)

    Prolyl Endopeptidase (PREP) mTOR Apoptosis PINK1/Parkin Cancer
    Salidroside (Standard) is the analytical standard of Salidroside. This product is intended for research and analytical applications. Salidroside (Rhodioloside) is a prolyl endopeptidase inhibitor. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling. Salidroside protects dopaminergic neurons by enhancing PINK1/Parkin-mediated mitophagy .
    Salidroside (Standard)
  • HY-B1834

    Drug Metabolite Inflammation/Immunology Cancer
    Megestrol is a synthetic progestin and used for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with an acquired immunodeficiency syndrome diagnosis .
    Megestrol
  • HY-129531

    Others Neurological Disease
    MuRF1-IN-1 is a muscle ring finger 1 (MuRF1) inhibitor that attenuates skeletal muscle atrophy and dysfunction in cardiac cachexia .
    MuRF1-IN-1
  • HY-18102
    GLPG0492
    5+ Cited Publications

    Androgen Receptor Others
    GLPG0492 is a non-steroidal selective androgen receptor modulator (potency 12 nM). GLPG0492 has the potential for the research of musculo-skeletal diseases such as sarcopenia and cachexia .
    GLPG0492
  • HY-B1834S1

    Isotope-Labeled Compounds Drug Metabolite Inflammation/Immunology
    Megestrol-d5 is the deuterium labeled Megestrol. Megestrol is a synthetic progestin and used for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with an acquired immunodeficiency syndrome diagnosis[1][2].
    Megestrol-d5
  • HY-B1834R

    Drug Metabolite Inflammation/Immunology Cancer
    Megestrol (Standard) is the analytical standard of Megestrol. This product is intended for research and analytical applications. Megestrol is a synthetic progestin and used for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with an acquired immunodeficiency syndrome diagnosis .
    Megestrol (Standard)
  • HY-14820

    EP-1572; AEZS-130

    GHSR Endocrinology Cancer
    Macimorelin (EP-1572), a GH secretagogue, is an orally active GHSR agonist. Macimorelin stimulates GH release. Macimorelin can be used in the research of adult growth hormone deficiency (AGHD), and Cancer anorexia-cachexia syndrome (CACS) .
    Macimorelin
  • HY-14820A

    EP-1572 acetate; AEZS-130 acetate

    GHSR Neurological Disease Endocrinology Cancer
    Macimorelin (EP-1572) acetate, a GH secretagogue, is an orally active GHSR agonist. Macimorelin acetate stimulates GH release. Macimorelin acetate can be used in the research of adult growth hormone deficiency (AGHD), and Cancer anorexia-cachexia syndrome (CACS) .
    Macimorelin acetate
  • HY-P99241
    Ponsegromab
    1 Publications Verification

    PF 06946860

    TGF-beta/Smad Cancer
    Ponsegromab (PF 06946860) is a potent and selective humanized anti-GDF15 monoclonal antibody with anti-cachexia activity. Ponsegromab binds to GDF15 and prevents the binding of GDF15 to GFRAL, thereby blocking GDF15/GFRAL-mediated signaling. Ponsegromab can be used in the research of cancers .
    Ponsegromab
  • HY-13676S

    Isotope-Labeled Compounds Progesterone Receptor Autophagy HIV Endocrinology Cancer
    Megestrol acetate-d3 is the deuterium labeled Megestrol acetate. Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia. Megestrol acetate decreases nuclear and cytosol androgen receptors human BPH tissue. Megestrol acetate has the potential for HIV study and downregulates autophagic catabolic pathway[1][2][3][4][5].
    Megestrol acetate-d3
  • HY-13676S1

    Isotope-Labeled Compounds Progesterone Receptor Autophagy HIV Endocrinology Cancer
    Megestrol acetate-d3-1 is deuterium labeled Megestrol acetate. Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia. Megestrol acetate decreases nuclear and cytosol androgen receptors human BPH tissue. Megestrol acetate has the potential for HIV study and downregulates autophagic catabolic pathway[1][2][3][4][5].
    Megestrol acetate-d3-1
  • HY-13676R
    Megestrol acetate (Standard)
    2 Publications Verification

    Progesterone Receptor Autophagy HIV Endocrinology Cancer
    Megestrol acetate (Standard) is the analytical standard of Megestrol acetate. This product is intended for research and analytical applications. Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia. Megestrol acetate decreases nuclear and cytosol androgen receptors human BPH tissue. Megestrol acetate has the potential for HIV study and downregulates autophagic catabolic pathway .
    Megestrol acetate (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: